BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 07, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/4 cls
Actelion Ltd. (SIX:ATLN) UBS Guillaume van Renterghem Price target Buy 18% CHF39.90
van Renterghem raised his target to CHF61 from CHF46 after macitentan met the primary endpoint in the Phase III SERAPHIN trial to treat pulmonary arterial hypertension (PAH) (see B16). Based on discussions with PAH experts, he believes the compound's morbidity and mortality benefit will "capture" at least 50% of new PAH patients receiving endothelin receptor antagonists, which could translate into CHF2.4B ($2.6B) in sales by 2025. Actelion plans to submit regulatory applications for macitentan to treat PAH, including an...

Read the full 656 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >